-
Nadolol (SQ-11725): A Translational PK Playbook
2026-08-25
A mechanistic and experimental framework for using Nadolol (SQ-11725) in cardiovascular models, with particular attention to beta-adrenergic signaling, transporter biology, pharmacokinetic variability, and translational study design.
-
CLK2 Inhibition and Platinum Resistance in Ovarian Cancer
2026-08-25
The reference study identifies Cdc2-like kinase 2 (CLK2) as an ovarian cancer resistance factor that phosphorylates BRCA1 at Ser1423, strengthening DNA damage repair after platinum exposure. Its tissue, cellular, and xenograft evidence supports CLK2 as a mechanistic target for studying platinum resistance, while also highlighting the need to distinguish CLK2-specific biology from broader Cdc2-like kinase and splicing effects.
-
G007-LK Tankyrase 1/2 Inhibitor Guide
2026-08-24
G007-LK is a selective tankyrase 1/2 inhibitor that suppresses TNKS1/2 auto-poly(ADP-ribosyl)ation and modulates Wnt/β-catenin signaling. Its nanomolar biochemical activity, cellular β-catenin degradation induction, and reported xenograft activity support use in mechanistic cancer biology research.
-
TG003 Cdc2-like kinase inhibitor: Lab Guide
2026-08-24
A scenario-based guide to using TG003 Cdc2-like kinase inhibitor (SKU B1431) in viability, proliferation, cytotoxicity, and alternative-splicing workflows. It connects dose interpretation, solvent control, assay optimization, and CLK2 cancer biology to practical, reproducible laboratory decisions.
-
p21 mRNA–LNP Delivery for Bladder Cancer
2026-08-23
The reference study develops an intravesical lipid nanoparticle system for transient delivery of chemically modified CDKN1A/p21 mRNA to bladder tumors. Its evidence links localized p21 restoration with cell-cycle inhibition, DNA-damage accumulation, apoptosis, and tumor suppression in an orthotopic mouse model, while also identifying the limitations that must be addressed before clinical translation.
-
Spiroplasma Entry into S2 Cells: Endocytic Routes
2026-08-22
Wei et al. established a Drosophila Schneider 2 cell model to show that Spiroplasma eriocheiris enters host cells through clathrin-mediated endocytosis and macropinocytosis, with additional dependence on actin filaments and microtubules. The study provides a useful pharmacological framework for dissecting bacterial uptake while highlighting the need to distinguish entry mechanisms from intracellular replication and cell injury.
-
Exo1 for Mechanism-Resolved EV Assays
2026-08-22
Exo1, or methyl 2-(4-fluorobenzamido)benzoate, is a rapid membrane-trafficking perturbation tool for separating Golgi–ER transport effects from extracellular-vesicle biology. This article presents a causal assay framework grounded in recent tumor extracellular-vesicle research, with practical controls and translational limits.
-
PPM-18 for NF-κB and iNOS Research
2026-08-21
PPM-18 offers a practical way to connect NF-κB activation with downstream iNOS expression, nitrite release, and inflammatory phenotypes. This workflow guide covers macrophage assays, sepsis research, bone-inflammation translation, compound handling, and troubleshooting without overstating evidence across model systems.
-
Cabazitaxel (XRP6258): Resistant-Model Guide
2026-08-20
Cabazitaxel (XRP6258, SKU B2157) provides a practical research option for antiproliferative assays involving taxane-resistant or P-glycoprotein-expressing cancer cell lines. It is water-insoluble, so workflows should use DMSO or ethanol, matched vehicle controls, prompt solution use, and carefully documented preparation rather than direct aqueous formulation.
-
Pazopanib Hydrochloride: Reading Drug Response
2026-08-20
Pazopanib Hydrochloride research becomes more informative when growth inhibition and cell death are measured separately. This guide combines GW786034 pharmacology with a decision framework for selecting endpoints, timing experiments, and interpreting anti-cancer assay data.
-
Pyridostatin: A Decision Framework for G4 Assays
2026-08-19
Pyridostatin and Pyridostatin TFA offer a precise way to interrogate G-quadruplex-dependent biology. This article presents a decision framework that separates DNA-based telomere experiments from emerging RNA G-quadruplex and TDP-43 applications.
-
In Vitro Drug Responses: Growth Inhibition and Cell Death
2026-08-19
Hannah R. Schwartz’s dissertation distinguishes relative viability from fractional viability when evaluating anticancer drug responses in vitro. Its central finding is that growth inhibition and cell death commonly occur together but differ in magnitude and timing, making separate endpoint analysis important for cancer research and assay interpretation.
-
Pazopanib Hydrochloride: Reliable Assay Design
2026-08-18
This scenario-driven guide shows how Pazopanib Hydrochloride, SKU A8347, can support more interpretable viability, proliferation, and cytotoxicity experiments. It connects target biology, concentration–time design, readout selection, and practical reagent criteria for cancer research.
-
DPPH Antioxidant Screening: Workflow and Tips
2026-08-18
Use DPPH for fast, plate-compatible ranking of antioxidant capacity in extracts, small molecules, and cultivation samples. This practical workflow combines colorimetric radical scavenging data with orthogonal assays and LC-MS/MS so promising hits can be prioritized without overstating biological relevance.
-
ATS-9R: Designing Adipose Gene-Silencing Studies
2026-08-17
ATS-9R, or Adipocyte-targeting sequence-9-arginine, combines Prohibitin recognition with arginine-rich nucleic acid delivery. This guide translates its GDM and adipose macrophage evidence into practical formulation, control, and assay decisions.